<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835286</url>
  </required_header>
  <id_info>
    <org_study_id>EHE0042</org_study_id>
    <nct_id>NCT03835286</nct_id>
  </id_info>
  <brief_title>Vitamin C to Reduce Vasopressor Dose in Septic Shock</brief_title>
  <acronym>ViCiS</acronym>
  <official_title>Vitamin C to Reduce Exogenous Vasopressor Dose in Septic Shock; a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Español de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Español de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, controlled, double blind clinical trial. Adult patients admitted to the ICU of
      the Hospital Español de México with a diagnosis of septic shock will be included.

      Patients will be randomized to one of the study groups:

      Intervention Group: Vitamin C 6 grams in 250 ml of 0.9% saline solution every 24 hours, in
      continuous infusion for 72 hours.

      Placebo Group: 0.9% saline solution 250 ml every 24 hours, in continuous infusion for 72
      hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, controlled, double blind clinical trial. Adult patients admitted to the ICU of
      the Hospital Español de México with a diagnosis of septic shock will be included.

      Patients will be randomized to one of the study groups:

      Intervention Group: Vitamin C 6 grams in 250 ml of 0.9% saline solution every 24 hours, in
      continuous infusion for 72 hours.

      Placebo Group: 0.9% saline solution 250 ml every 24 hours, in continuous infusion for 72
      hours.

      Bottles will be identical, only identified by the sequential number of the patient that has
      been included.

      Primary objective is to demonstrate that the administration of intravenous Vitamin C
      decreases the dose of exogenous vasopressors in patients with septic shock
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressor dose</measure>
    <time_frame>72 hours</time_frame>
    <description>Hourly dose of exogenous vasopressor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hours of vasopressor use</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Total hours of vasopressor use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of mechanical ventilation</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Total days of mechanical ventilation use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Intensive Care Unit stay</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Total days of intensive care unit stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in Intensive Care Unit</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Rate of intensive care mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C experimental group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos Controlled group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.</description>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  Septic Shock

        Exclusion Criteria:

          -  Previous treatment exceeded 24 hours

          -  Refusal to participate

          -  Do Not Resuscitate

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Martinez-Zubieta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Español de Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose J Zaragoza, MD</last_name>
    <phone>+52 5552559600</phone>
    <phone_ext>1111</phone_ext>
    <email>zaragozagalvan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Español</name>
      <address>
        <city>Mexico City</city>
        <zip>11520</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose J Zaragoza, MD</last_name>
      <phone>+525552559600</phone>
      <phone_ext>1111</phone_ext>
      <email>zaragozagalvan@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Martinez, MD</last_name>
      <phone>+525552559600</phone>
      <phone_ext>1111</phone_ext>
      <email>ricardomz@prodigy.net.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Español de Mexico</investigator_affiliation>
    <investigator_full_name>Jose J Zaragoza</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>critical care</keyword>
  <keyword>vitamin C</keyword>
  <keyword>vasopressor</keyword>
  <keyword>intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Complete database will be shared as requested by the publishing journal, once the study is completed</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Available one year after</ipd_time_frame>
    <ipd_access_criteria>Journal provided</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

